Search Results - "REICH, Steven D"

Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results by RUGO, Hope S, HERBST, Roy S, LIU, Glenn, PARK, John W, KIES, Merrill S, STEINFELDT, Heidi M, PITHAVALA, Yazdi K, REICH, Steven D, FREDDO, James L, WILDING, George

“…We studied the safety, clinical activity, and pharmacokinetics (PK) of AG-013736, an oral receptor tyrosine kinase inhibitor of vascular endothelial cell…”
Get full text

Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study by LIU, Glenn, RUGO, Hope S, CHARNSANGAVEJ, Chusilp, PARK, John W, ASHTON, Edward A, STEINFELDT, Heidi M, PITHAVALA, Yazdi K, REICH, Steven D, HERBST, Roy S, WILDING, George, MCSHANE, Teresa M, EVELHOCH, Jeffrey L, NG, Chaan, JACKSON, Edward, KELCZ, Frederick, YEH, Benjamin M, LEE, Fred T

“…Identifying suitable markers of biologic activity is important when assessing novel compounds such as angiogenesis inhibitors to optimize the dose and schedule…”
Get full text

A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer by Lin, Jianqing, M.D, Zahurak, Marianna, M.S, Beer, Tomasz M., M.D, Ryan, Charles J., M.D, Wilding, George, M.D, Mathew, Paul, M.D, Morris, Michael, M.D, Callahan, Jennifer A., M.A.S, Gordon, Gilad, M.D, Reich, Steven D., M.D, Carducci, Michael A., M.D, Antonarakis, Emmanuel S., M.D

“…Abstract Objective ATN-224 (choline tetrathiomolybdate) is an oral Cu2+ /Zn2+ -superoxide dismutase 1 (SOD1) inhibitor with preclinical antitumor activity. We…”
Get full text

A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (NPI‐0052‐107): final study results by Spencer, Andrew, Harrison, Simon, Zonder, Jeffrey, Badros, Ashraf, Laubach, Jacob, Bergin, Krystal, Khot, Amit, Zimmerman, Todd, Chauhan, Dharminder, Levin, Nancy, MacLaren, Ann, Reich, Steven D., Trikha, Mohit, Richardson, Paul

“…Summary Marizomib (MRZ) is an irreversible, pan‐subunit proteasome inhibitor (PI) in clinical development for relapsed/refractory multiple myeloma (RRMM) and…”
Get full text

Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results by Harrison, Simon J, Mainwaring, Paul, Price, Timothy, Millward, Michael J, Padrik, Peeter, Underhill, Craig R, Cannell, Paul K, Reich, Steven D, Trikha, Mohit, Spencer, Andrew

“…Marizomib (NPI-0052) is an irreversible proteasome inhibitor, derived from a marine actinomycete, with activity and specificity that is distinct from other…”
Get full text

Multi-Institutional Phase I/II Trial of Oral Bexarotene in Combination With Cisplatin and Vinorelbine in Previously Untreated Patients With Advanced Non–Small-Cell Lung Cancer by KHURI, Fadlo R, RIGAS, James R, HONG, Waun K, FIGLIN, Robert A, GRALLA, Richard J, SHIN, Dong M, MUNDEN, Reginald, FOX, Nikolaus, MI RA HUYGHE, YIN KEAN, REICH, Steven D

“…Bexarotene (Targretin; Ligand Pharmaceuticals, Inc, San Diego, CA) is a retinoid-X-receptor (RXR)-selective retinoid with preclinical antitumor activity in…”
Get full text

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients by Levin, Nancy, Spencer, Andrew, Harrison, Simon J., Chauhan, Dharminder, Burrows, Francis J., Anderson, Kenneth C., Reich, Steven D., Richardson, Paul G., Trikha, Mohit

“…Summary Proteasome inhibitors (PIs) are highly active in multiple myeloma (MM) but resistance is commonly observed. All clinical stage PIs effectively inhibit…”
Get full text

A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF‐05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327‐01) by Yin, Donghua, Barker, Kerry B., Li, Ruifeng, Meng, Xu, Reich, Steven D., Ricart, Alejandro D., Rudin, Dan, Taylor, Carrie T., Zacharchuk, Charles M., Hansson, Arne G.

“…Aims The pharmacokinetic (PK) similarity between PF‐05280014, a proposed trastuzumab biosimilar, trastuzumab sourced from European Union (trastuzumab‐EU) or…”
Get full text

First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors by Shapiro, Geoffrey I., Vaishampayan, Ulka N., LoRusso, Patricia, Barton, Jeremy, Hua, Steven, Reich, Steven D., Shazer, Ronald, Taylor, Carrie T., Xuan, Dawei, Borghaei, Hossein

“…Summary Background The antibody-drug conjugate PF-06263507 targets the cell-surface, tumor-associated antigen 5T4 and consists of a humanized IgG1 conjugated…”
Get full text

Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data by Bota, Daniela A, Mason, Warren, Kesari, Santosh, Magge, Rajiv, Winograd, Benjamin, Elias, Ileana, Reich, Steven D, Levin, Nancy, Trikha, Mohit, Desjardins, Annick

“…This phase I/II trial in patients with recurrent glioblastoma (GBM) evaluates the safety and preliminary efficacy of marizomib, an irreversible pan-proteasome…”
Get full text

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas by MITA, Monica M, SPEAR, Matthew A, PILAT, Maryjo, LLOYD, G. Kenneth, NEUTEBOOM, Saskia T. C, CROPP, Gillian, ASHTON, Edward, LORUSSO, Patricia M, YEE, Lorrin K, MITA, Alain C, HEATH, Elisabeth I, PAPADOPOULOS, Kyriakos P, FEDERICO, Kristine C, REICH, Steven D, ROMERO, Ofelia, MALBURG, Lisa

“…Plinabulin (NPI-2358) is a vascular disrupting agent that elicits tumor vascular endothelial architectural destabilization leading to selective collapse of…”
Get full text

Evaluating imbalances of adverse events during biosimilar development by Vana, Alicia M., Freyman, Amy W., Reich, Steven D., Yin, Donghua, Li, Ruifeng, Anderson, Scott, Jacobs, Ira A., Zacharchuk, Charles M., Ewesuedo, Reginald

“…Biosimilars are designed to be highly similar to approved or licensed (reference) biologics and are evaluated based on the totality of evidence from extensive…”
Get full text

Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial by Heald, Peter, Mehlmauer, Marilyn, Martin, Ann G, Crowley, Constance A, Yocum, Richard C, Reich, Steven D

“…We sought to determine the safety and efficacy of topical bexarotene (Targretin; Ligand Pharmaceuticals, La Jolla, Calif) gel 1% in patients with refractory or…”
Get full text

The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) by Giles, Francis J., Bellamy, William T., Estrov, Zeev, O’Brien, Susan M., Verstovsek, Srdan, Ravandi, Farhad, Beran, Miloslav, Bycott, Paul, Pithavala, Yazdi, Steinfeldt, Heidi, Reich, Steven D., List, Alan F., Yee, Karen W.L.

“…AG-013736 is an oral anti-angiogenesis agent with activity against a variety of receptor tyrosine kinases, including VEGFR-1, VEGFR-2, VEGFR-3, c-kit, and…”
Get full text

Correlation of therapy-induced neutropenia with survival in patients with metastatic pancreatic cancer treated with GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study by Ugolkov, Andrey, Koukol, Austin, Kellinger, Caroline, Smith, Sheri Lynn, Gallipoli, Susan, Gagnon, Suzanne, Seifarth, Chris, Reich, Steven D., Mazar, Andrew Paul

“…e16311 Background: Previously, elraglusib (9-ING-41), an inhibitor of Glycogen Synthase Kinase-3 (GSK-3), was shown to potentiate the anticancer effects of…”
Get full text

Phase 1, multicenter, open-label, dose-escalation, study of marizomib (MRZ) and bevacizumab (BEV) in WHO grade IV malignant glioma (G4 MG) by Bota, Daniela Annenelie, Desjardins, Annick, Mason, Warren P., Fine, Howard Alan, Reich, Steven D., Trikha, Mohit

“…Abstract only…”
Get full text

The plinabulin/docetaxel combination to mitigate the known safety concerns of docetaxel by Mohanlal, Ramon, Aren, Osvaldo Rudy, Polikoff, Jonathan, Reich, Steven D., Mikrut, William, Huang, Lan, Bazhenova, Lyudmila

“…Abstract only…”
Get full text

Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM) by Mason, Warren P., Kesari, Santosh, Stupp, Roger, Aregawi, Dawit Gebremichael, Piccioni, David Eric, Roth, Patrick, Desjardins, Annick, Reich, Steven D., Casadebaig, Marie-Laure, Elias, Ileana, Winograd, Benjamin, Levin, Nancy, Bota, Daniela Annenelie

“…Abstract only 2021 Background: Proteasome inhibition sensitizes glioma cells to TMZ and RT, providing a novel therapeutic strategy for GBM. MRZ, an…”
Get full text

ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) ± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM) by Bota, Daniela, Desjardins, Annick, Mason, Warren, Kesari, Santosh, Magge, Rajiv, Winograd, Benjamin, Reich, Steven D, Levin, Nancy, Trikha, Mohit

“…MRZ – an irreversible, brain-penetrant, pan-proteasome inhibitor with anti-glioma preclinical activity – was evaluated in BEV-naïve rGBM patients…”
Get full text

ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS by Bota, Daniela A, Kesari, Santosh, Piccioni, David, Aregawi, Dawit, Roth, Patrick, Stupp, Roger, Desjardins, Annick, Reich, Steven D, Elias, Ileana, Li, Mingyu, Levin, Nancy, Winograd, Benjamin, Mason, Warren

“…Abstract Proteasome inhibition sensitizes glioma cells to TMZ and RT, providing a novel therapeutic strategy for ndGBM. MRZ, an irreversible, brain-penetrant,…”
Get full text